{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:43:39Z","timestamp":1782999819106,"version":"3.54.5"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"unspecified","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,2,14]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In January 2024, all people with multiple sclerosis (pwMS) treated with natalizumab (NTZ) at Oslo University Hospital were switched from originator to biosimilar NTZ. We prospectively evaluated disease activity, safety, serum drug levels, immunogenicity and biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational study included 39 pwMS switching to biosimilar NTZ. Clinical relapses, MRI activity and side effects were recorded. NTZ levels and anti-drug antibodies (ADAb) by in-house assays; anti-John Cunningham virus (JCV) antibodies by Stratify (Biogen) and Immunowell (Sandoz) platforms; leucocytes and serum levels of neurofilament light chain (NfL) and glial fibrillar acidic protein (GFAP) were measured by Mesoscale platform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven pwMS (28%) reported new side effects, most commonly fatigue, headache and muscle pain. Mean NTZ levels were 15.1\u2009mg\/L before and 14.9\u2009mg\/L after switching (difference \u20130.3, 95%\u2009CI \u20131.4 to 0.8). ADAb was detected in one pwMS, unchanged after switch. The proportion of JCV-positive cases increased from 13% (Stratify) to 52% (Immunowell), leading four pwMS to discontinue NTZ. Leukocytes were stable after switch. Median NfL remained stable (45.3 vs 44.0\u2009pg\/mL; median difference \u20131.3, 95%\u2009CI \u20136.0 to 3.5), whereas GFAP decreased (23.0 vs 20.5\u2009pg\/mL; difference \u20132.5, 95%\u2009CI \u20134.7 to \u20130.3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching from originator to biosimilar NTZ was associated with stable disease activity. Drug levels, ADAb, leukocytes and NfL remained similar before and after switching, and GFAP decreased, of uncertain relevance. The marked rise in JCV-positivity on the Immunowell assay underscores the need for harmonisation of anti-JCV antibody testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2025-001477","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:20:24Z","timestamp":1773872424000},"page":"e001477","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-2111","authenticated-orcid":false,"given":"Einar August","family":"H\u00f8gest\u00f8l","sequence":"first","affiliation":[{"name":"Department of Neurology, Akershus University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Department of Psychology, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-3173","authenticated-orcid":false,"given":"\u00c5ge Winje","family":"Brustad","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9127-6488","authenticated-orcid":false,"given":"Elisabeth Gulowsen","family":"Celius","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Meling","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0925-8879","authenticated-orcid":false,"given":"P\u00e5l","family":"Berg-Hansen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4747-9453","authenticated-orcid":false,"given":"Grete Birkeland","family":"Kro","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6242-9804","authenticated-orcid":false,"given":"Marton","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2992-7195","authenticated-orcid":false,"given":"Ylva","family":"Schanke","sequence":"additional","affiliation":[{"name":"Research Institute for Internal Medicine, Division of Surgery and specialized Medicine, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6529-6485","authenticated-orcid":false,"given":"Bente","family":"Halvorsen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Research Institute for Internal Medicine, Division of Surgery and specialized Medicine, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-1282","authenticated-orcid":false,"given":"David J","family":"Warren","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-0223","authenticated-orcid":false,"given":"Johanna E","family":"Gehin","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3633-8428","authenticated-orcid":false,"given":"Nils","family":"Bolstad","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4913-8567","authenticated-orcid":false,"given":"Gro Owren","family":"Nygaard","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2026070205500698000_8.1.e001477.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"2026070205500698000_8.1.e001477.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30067-3"},{"key":"2026070205500698000_8.1.e001477.3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamaneurol.2022.5007","article-title":"Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial","volume":"80","author":"Hemmer","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026070205500698000_8.1.e001477.4","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.37765\/ajmc.2024.89558","article-title":"Budget impact analysis of biosimilar natalizumab in the US","volume":"30","author":"Li","year":"2024","journal-title":"Am J Manag Care"},{"key":"2026070205500698000_8.1.e001477.5","doi-asserted-by":"crossref","first-page":"104841","DOI":"10.1016\/j.msard.2023.104841","article-title":"A place for biosimilars in the changing multiple sclerosis treatment landscape","volume":"77","author":"Greenberg","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"2026070205500698000_8.1.e001477.6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1414304","article-title":"Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile","volume":"15","author":"Chamberlain","year":"2024","journal-title":"Front Immunol"},{"key":"2026070205500698000_8.1.e001477.7","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1177\/13524585251346652","article-title":"A comparison of JC virus assay performance provided with originator and biosimilar natalizumab","volume":"31","author":"Varley","year":"2025","journal-title":"Mult Scler"},{"key":"2026070205500698000_8.1.e001477.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r403","article-title":"Multiple sclerosis: Investigation into side effects of switching patients to natalizumab biosimilar","volume":"388","author":"Mahase","year":"2025","journal-title":"BMJ"},{"key":"2026070205500698000_8.1.e001477.9","doi-asserted-by":"crossref","first-page":"101009","DOI":"10.1016\/j.lanepe.2024.101009","article-title":"Fluid biomarkers in multiple sclerosis: from current to future applications","volume":"44","author":"Di Filippo","year":"2024","journal-title":"The Lancet Regional Health - Europe"},{"key":"2026070205500698000_8.1.e001477.10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/ijms252313153","article-title":"Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients","volume":"25","author":"Sainz-Amo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026070205500698000_8.1.e001477.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30282-X"},{"key":"2026070205500698000_8.1.e001477.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00143-0"},{"key":"2026070205500698000_8.1.e001477.13","doi-asserted-by":"crossref","DOI":"10.1177\/11795735221135485","article-title":"Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience","volume":"14","author":"Perncezky","year":"2022","journal-title":"J Cent Nerv Syst Dis"},{"key":"2026070205500698000_8.1.e001477.14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/13524585251346658","article-title":"Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing","volume":"31","author":"Ziemssen","year":"2025","journal-title":"Mult Scler"},{"key":"2026070205500698000_8.1.e001477.15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/13524585241300972","article-title":"Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice","volume":"31","author":"Inojosa","year":"2025","journal-title":"Mult Scler"},{"key":"2026070205500698000_8.1.e001477.16","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/13524585251322683","article-title":"Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?","volume":"31","author":"Vukusic","year":"2025","journal-title":"Mult Scler"},{"key":"2026070205500698000_8.1.e001477.17","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaneurol.2025.0337","article-title":"Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis","volume":"82","author":"Gelissen","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026070205500698000_8.1.e001477.18","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2665-9913(23)00341-7","article-title":"Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials","volume":"6","author":"Brun","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026070205500698000_8.1.e001477.19","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511404271"},{"key":"2026070205500698000_8.1.e001477.20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/alz.092387","article-title":"Analytical Validation of MSD S\u2010PLEX Neurology Panel 1","volume":"20","author":"Demos","year":"2024","journal-title":"Alzheimer's & Dementia"},{"key":"2026070205500698000_8.1.e001477.21","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40259-024-00671-4","article-title":"Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab","volume":"38","author":"Selmaj","year":"2024","journal-title":"BioDrugs"},{"key":"2026070205500698000_8.1.e001477.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222155"},{"key":"2026070205500698000_8.1.e001477.23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.035"},{"key":"2026070205500698000_8.1.e001477.24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307883"},{"key":"2026070205500698000_8.1.e001477.25","doi-asserted-by":"crossref","first-page":"101498","DOI":"10.1016\/j.msard.2019.101498","article-title":"Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation","volume":"38","author":"Mustonen","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2026070205500698000_8.1.e001477.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3734-4","article-title":"Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)","volume":"21","author":"Syversen","year":"2020","journal-title":"Trials"},{"key":"2026070205500698000_8.1.e001477.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4172"},{"key":"2026070205500698000_8.1.e001477.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.21316"},{"key":"2026070205500698000_8.1.e001477.29","unstructured":"Adler F , Andersen M , Bartl T , et al . A new assay for detection of anti-jcv antibodies to support risk stratification and monitoring for progressive multifocal leukoencephalopathy in patients considering or in treatment with natalizumab. 2nd Annual BCTRIMS\u2013ECF Joint Meeting Virtual, 2024"},{"key":"2026070205500698000_8.1.e001477.30","doi-asserted-by":"crossref","first-page":"106541","DOI":"10.1016\/j.msard.2025.106541","article-title":"Approach to JCV testing with natalizumab biosimilar: a UK consensus statement","volume":"100","author":"Dobson","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"2026070205500698000_8.1.e001477.31","first-page":"jnnp","article-title":"Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)","volume":"95","author":"Toorop","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026070205500698000_8.1.e001477.32","doi-asserted-by":"crossref","first-page":"105605","DOI":"10.1016\/j.msard.2024.105605","article-title":"Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review","volume":"86","author":"Brown","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2026070205500698000_8.1.e001477.33","first-page":"e1452","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology (ECronicon)"},{"key":"2026070205500698000_8.1.e001477.34","doi-asserted-by":"crossref","first-page":"106298","DOI":"10.1016\/j.msard.2025.106298","article-title":"Analysis of serum natalizumab concentrations obtained during routine clinical care in patients with multiple sclerosis: A cross-sectional study","volume":"94","author":"Moskorova","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"2026070205500698000_8.1.e001477.35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1474651409355454","article-title":"Lessons learned from biosimilar epoetins and insulins","volume":"10","author":"Kuhlmann","year":"2010","journal-title":"Diabetes & Vascular Disease"},{"key":"2026070205500698000_8.1.e001477.36","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.68"},{"key":"2026070205500698000_8.1.e001477.37","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241300047","article-title":"Clinical and radiological implications of subpotent generic fingolimod in multiple sclerosis: a case series","volume":"17","author":"Okuda","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"2026070205500698000_8.1.e001477.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"2026070205500698000_8.1.e001477.39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026070205500698000_8.1.e001477.40","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis","volume":"10","author":"Barro","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:50:31Z","timestamp":1782996631000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,18]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjno-2025-001477"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001477","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}